Vascularization strategies enhance beta cell replacement therapies for the treatment of Type 1 Diabetes

Yasaman Aghazadeh, PhD

Research Associate
Terrence Donnelly Center for Cellular and Biomolecular Research
University of Toronto

Special Conference: This speaker is a candidate for the Research Unit Director position available at the IRCM.

---

In person: 
IRCM Auditorium
110, avenue des Pins O, H2W 1R7 Montreal
Wearing a mask is mandatory at all times

Online:
Zoom Link : https://zoom.us/j/94078486709
ID : 940 7848 6709
Code : 785826

This conference is set to occur under a hybrid format. However, please note that last-minute changes to online-only lecture may occur due to unforeseen circumstances. We invite you to visit this webpage again a few days before attending.

---

About the conference : 
Type 1 diabetes (T1D) is one of the most pervasive chronic diseases and currently affects 1% of the Canadian population, with its prevalence on a steep rise. Canada has been the frontliner in developing therapies for T1D, as it is the birthplace of insulin, which changed T1D from a fatal disease to a manageable one, as well as islet transplantation, which is the only long-term treatment of T1D. However, islet transplantation is limited by donor scarcity, and its success rate is challenged by poor cell survival post-transplantation. My research focuses on developing beta cells from human pluripotent stem cell sources to overcome donor scarcity and implementing robust vascularization strategies to improve cell survival post-transplantation and enhance beta cell endocrine function. This research has a high potential for clinical translation to treat T1D and develops a platform to recapitulate the islet niche in vitro for the first time, to study beta cell development in health and T1D.

To make sure you don't miss any of the IRCM conferences, sign up now for our newsletter!